健民集团(600976.SH)：呋塞米口服溶液获批上市

Core Viewpoint - The approval of the oral solution of Furosemide by Jianmin Group represents a significant advancement in the treatment options for conditions such as heart failure, liver cirrhosis, and kidney-related edema, as well as hypertension [1] Company Summary - Jianmin Group has received approval from the National Medical Products Administration for its Furosemide oral solution [1] - The oral solution is a high-efficiency diuretic, which is more suitable for children compared to traditional tablet and injection forms, enhancing medication safety and adherence [1] - The developed product has the same active ingredients, excipients, dosage form, specifications, indications, administration routes, and dosages as the reference original preparation, indicating its clinical application value [1] Industry Summary - The introduction of the oral solution will provide more treatment options in the relevant disease areas, potentially impacting the market for diuretics and related medications [1]